Episode Details

UVM Health is cutting coverage for GLP-1 weight-loss drugs, saving $19 million a year—but at what cost? While leaders say it’s needed to fix a financial crisis, employees who’ve seen life-changing health improvements from these meds see it as a step backward. The move ignores potential long-term savings from fewer specialist visits and chronic disease complications. Instead of a full ban, smarter options like prior authorization or risk-based coverage could balance cost and care.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/83afd7d17d4e60ac